Keystone Heart acquires 510 Kardiac Devices

Keystone Heart today said it has acquired 510 Kardiac Devices for an undisclosed amount. The […]

Keystone Heart today said it has acquired 510 Kardiac Devices for an undisclosed amount.
The development-stage 510 Kardiac Devices is currently developing the Lim Transseptal System to meet the demands of left-sided structural heart procedures that require a transeptal approach. The system is important in procedures such as percutaneous treatment of mitral valve disease, percutaneous occlusion of the left atrial appendage and electrophysiology procedures.
“At Keystone Heart, we are dedicated to delivering innovative products that fulfill unmet needs—like our TriGUARD 3, which is the only CE Marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures,” president and CEO Chris Richardson said in a news release. “With the increase in left-sided structural heart procedures, Interventional Cardiologists are being asked to puncture and cross the interatrial septum using specific puncture locations on challenging anatomies. Adding the Lim Transseptal System allows us to broaden our portfolio and fortify our long-term strategy of offering total package solutions for structural heart procedures.”
The Lim Transseptal System device is designed to give physicians an increased level of device control, functionality and visibility to make transseptal punctures more effective and efficient. Its intuitive handle design allows steering in two unique planes, as well as the ability to advance the dilator with precise and controlled ability. It also uses fluoroscopic and echogenic markers on the distal end to increase visibility.
“We are excited to be joining an innovative company like Keystone Heart,” said Jaime Sarabia, 510 Kardiac Devices co-founder and CEO. “Procedures requiring a transseptal approach will grow dramatically over the next several years, and the Lim Transseptal System will help to differentiate Keystone Heart as a leader within these new therapies. This partnership provides us the distinct opportunity to bring our pioneering technology into the US & Europe by partnering with a team that is known for excellent product development and go-to-market experience.”
The device is currently not cleared for use in the U.S., not approved for commercial distribution and is not CE marked.
Original Article: (